Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano Genomics's Total Assets for the quarter that ended in Mar. 2026 was MXN1,168.6 Mil.
During the past 12 months, Bionano Genomics's average Total Assets Growth Rate was -16.30% per year.
During the past 3 years, the average Total Assets Growth Rate was -34.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.90% per year.
During the past 10 years, Bionano Genomics's highest 3-Year average Total Assets Growth Rate was 148.10%. The lowest was -34.60%. And the median was 34.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Bionano Genomics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Bionano Genomics Total Assets Related Terms
Bionano Genomics Total Assets Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Bionano Genomics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (MEX:BNGO) has a Total Assets of MXN1,168.6 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Bionano Genomics and its competitors.
Is Bionano Genomics' Total Assets too high?
Bionano Genomics' current Total Assets is MXN1,168.6 Mil. Overall, Bionano Genomics has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Total Assets compare to UEEC and CUPR?
Bionano Genomics' Total Assets of MXN1,168.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bionano Genomics and its competitors. Bionano Genomics's current Total Assets is MXN1,168.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN26.39, compared to a current price of MXN20.09 — trading 23.9% below its estimated fair value. The current Total Assets is MXN1,168.6 Mil. Bionano Genomics' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Total Assets is MXN1,168.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of MXN20.09 is trading 23.9% below its estimated GF Value™ of MXN26.39.
GuruFocus considers Bionano Genomics to be Modestly Undervalued.
Key valuation signals for MEX:BNGO:
Total Assets: MXN1,168.6 Mil
GF Value™: MXN26.39 vs. price of MXN20.09 (23.9% below fair value)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
60GF Score
Get the complete analysis for MEX:BNGO
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
